NO991151L - Forbindelse og anvendelse derav - Google Patents

Forbindelse og anvendelse derav

Info

Publication number: NO991151L
Authority: NO; Norway
Prior art keywords: compound; lamotrigine; triazin; amino; sample
Prior art date: 1998-06-10

Application number

NO991151A

Other languages

English (en)

Norwegian (no)

Other versions

NO991151D0 (no

Inventor

Lorraine Mary Edmeades

Nigel Arthur Griffith-Skinner

Derek Anthony Hill

Graham Thronton Hill

Terence William Packham

Original Assignee

Wellcome Found

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-06-10

Filing date

1999-03-10

Publication date

1999-12-13

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10833464&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO991151(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-03-10 Application filed by Wellcome Found filed Critical Wellcome Found

1999-03-10 Publication of NO991151D0 publication Critical patent/NO991151D0/no

1999-12-13 Publication of NO991151L publication Critical patent/NO991151L/no

Links

150000001875 compounds Chemical class 0.000 title abstract 3
PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 abstract 2
229960001848 lamotrigine Drugs 0.000 abstract 2
OVNGWOHWYFBGKF-UHFFFAOYSA-N 3-amino-6-(2,3-dichlorophenyl)-2h-1,2,4-triazin-5-one Chemical compound OC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl OVNGWOHWYFBGKF-UHFFFAOYSA-N 0.000 abstract 1
229940126062 Compound A Drugs 0.000 abstract 1
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 abstract 1
230000015556 catabolic process Effects 0.000 abstract 1
238000006731 degradation reaction Methods 0.000 abstract 1
239000002552 dosage form Substances 0.000 abstract 1
238000010998 test method Methods 0.000 abstract 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D253/075—Two hetero atoms, in positions 3 and 5
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/90—Plate chromatography, e.g. thin layer or paper chromatography
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/145555—Hetero-N
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/145555—Hetero-N
- Y10T436/147777—Plural nitrogen in the same ring [e.g., barbituates, creatinine, etc.]

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Analytical Chemistry (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Pharmacology & Pharmacy (AREA)
Food Science & Technology (AREA)
Medicinal Chemistry (AREA)
Physics & Mathematics (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
Biophysics (AREA)
General Physics & Mathematics (AREA)
Immunology (AREA)
Pathology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Investigating Or Analysing Biological Materials (AREA)
Plural Heterocyclic Compounds (AREA)
Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
Medicinal Preparation (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

NO991151A 1998-06-10 1999-03-10 Forbindelse og anvendelse derav NO991151L (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB9812413.4A GB9812413D0 (en)	1998-06-10	1998-06-10	Compound and its use

Publications (2)

Publication Number	Publication Date
NO991151D0 NO991151D0 (no)	1999-03-10
NO991151L true NO991151L (no)	1999-12-13

Family

ID=10833464

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO991151A NO991151L (no)	1998-06-10	1999-03-10	Forbindelse og anvendelse derav
NO20032753A NO20032753D0 (no)	1998-06-10	2003-06-17	Forbindelse og anvendelse derav

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NO20032753A NO20032753D0 (no)	1998-06-10	2003-06-17	Forbindelse og anvendelse derav

Country Status (31)

Country	Link
US (1)	US6333198B1 (id)
EP (2)	EP1170588A1 (id)
JP (1)	JP2989189B1 (id)
KR (1)	KR100322354B1 (id)
CN (2)	CN1238454A (id)
AP (3)	AP9901481A0 (id)
AR (1)	AR014074A1 (id)
AT (1)	ATE218552T1 (id)
AU (1)	AU2031999A (id)
BR (1)	BR9900984A (id)
CA (1)	CA2265194C (id)
DE (1)	DE69901656T2 (id)
DK (1)	DK0963980T3 (id)
EA (1)	EA000666B1 (id)
ES (1)	ES2178342T3 (id)
GB (1)	GB9812413D0 (id)
HR (1)	HRP990074A2 (id)
HU (1)	HUP9900592A3 (id)
ID (1)	ID22957A (id)
MA (1)	MA24777A1 (id)
NO (2)	NO991151L (id)
NZ (1)	NZ334590A (id)
PE (1)	PE20000332A1 (id)
PL (1)	PL331870A1 (id)
PT (1)	PT963980E (id)
SG (1)	SG85628A1 (id)
SI (1)	SI0963980T1 (id)
TR (1)	TR199900520A3 (id)
UY (1)	UY25946A1 (id)
YU (1)	YU12399A (id)
ZA (1)	ZA991951B (id)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020055177A1 (en) *	1999-03-10	2002-05-09	Glaxo Wellcome Inc.	Compound and its use
WO2001049669A1 (en) *	2000-01-03	2001-07-12	Rpg Life Sciences Limited	A process for the preparation of 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine, commonly known as lamotrigine
US7335380B2 (en)	2000-12-29	2008-02-26	Synthon Ip Inc.	Amlodipine free base
BR0116553A (pt)	2000-12-29	2004-02-03	Pfizer Ltd	Composto, composição farmacêutica para tratamento de angina ou hipertensão, processo, processo para tratamento ou prevenção de angina ou hipertensão, composição de ingredientes farmaceuticamente ativos, composição farmacêutica para tratamento ou prevenção de angina ou hipertensão e processo para tratar ou prevenir angina ou hipertensão
CA2433284A1 (en) *	2000-12-29	2002-07-11	Pfizer Limited	Reference standards and processes for determining the purity or stability of amlodipine maleate
MXPA03005882A (es)	2000-12-29	2005-04-19	Pfizer Ltd	Derivado amida de amlodipina.
CA2433181C (en)	2000-12-29	2005-11-22	Pfizer Limited	Amlodipine hemifumarate
BR0116552A (pt)	2000-12-29	2004-02-03	Pfizer Ltd	Hemi-maleato de amlodipina, processo, método para o tratamento ou prevenção de angina ou hipertensão, composição farmacêutica, para uso no tratamento e/ou de angina ou da hipertensão
US6653481B2 (en)	2000-12-29	2003-11-25	Synthon Bv	Process for making amlodipine
AT5874U1 (de)	2000-12-29	2003-01-27	Bioorg Bv	Pharmazeutische zubereitungen enthaltend amlodipinmaleat
RS53403A (sr)	2000-12-29	2006-10-27	Pfizer Limited	Postupak za dobijanje amlodipin maleata
WO2002053541A1 (en)	2000-12-29	2002-07-11	Pfizer Limited	Amide derivative of amlodipine
DE10134980C2 (de) *	2001-07-17	2003-05-28	Helm Ag	Verfahren zur Herstellung von Lamotrigin
CA2366521C (en)	2001-12-24	2007-03-06	Brantford Chemicals Inc.	A new and efficient process for the preparation of lamotrigine and related 3,5-diamino-6-substituted-1,2,4-triazines
IL164155A0 (en) *	2002-03-20	2005-12-18	Teva Pharma	Crystalline forms of quetiapine hemifumarate
HU225667B1 (en)	2002-09-20	2007-05-29	Richter Gedeon Nyrt	Method for producing high-purity 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine
ES2209639B1 (es)	2002-10-31	2005-08-01	Vita Cientifica, S.L.	Procedimiento para la obtencion de un compuesto farmaceuticamente activo y obtencion de su intermedio.
GB2395483A (en) *	2003-07-03	2004-05-26	Jubilant Organosys Ltd	Crystalline lamotrigine and its monohydrate
CA2537271A1 (en)	2003-08-28	2005-03-17	Teva Pharmaceutical Industries, Ltd.	Process for preparation of rosuvastatin calcium
WO2005051921A1 (en) *	2003-11-24	2005-06-09	Teva Pharmaceutical Industries Ltd.	Crystalline ammonium salts of rosuvastatin
KR100887264B1 (ko) *	2003-12-02	2009-03-06	테바 파마슈티컬 인더스트리즈 리미티드	로수바스타틴의 특성화를 위한 기준 표준물
US7851624B2 (en) *	2003-12-24	2010-12-14	Teva Pharamaceutical Industries Ltd.	Triol form of rosuvastatin and synthesis of rosuvastatin
CA2554572A1 (en) *	2004-01-30	2005-08-18	Teva Pharmaceutical Industries Ltd.	Montelukast free acid polymorphs
WO2005075427A2 (en) *	2004-01-30	2005-08-18	Teva Pharmaceutical Industries Ltd.	Montelukast sodium polymorphs
MD2823G2 (ro) *	2004-02-12	2006-05-31	Институт Химии Академии Наук Молдовы	Procedeu de determinare cantitativă a sclareolului în extractele, obţinute din salvia de muscat
EP1646612B1 (en) *	2004-04-21	2009-07-01	Teva Pharmaceutical Industries Ltd	Processes for preparing montelukast sodium
US7683188B2 (en)	2004-04-26	2010-03-23	TEVA Gyógyszergyár Zártkōrūen Mūkōdō Részvénytársaság	Process for preparation of mycophenolic acid and ester derivatives thereof
MXPA06005658A (es) *	2004-04-27	2007-04-10	Teva Gyogyszergyar Zartkoruen	Proceso para preparacion de micofenolato mofetil, y otros esteres de acido micofenolico.
US7439399B2 (en) *	2004-06-28	2008-10-21	Teva Pharmaceutical Fine Chemicals	Processes for the preparation of atomoxetine hydrochloride
WO2006004976A2 (en) *	2004-06-28	2006-01-12	Teva Pharmaceutical Fine Chemicals S.R.L.	Process for the preparation of atomoxetine hydrochloride
US7179916B2 (en) *	2004-07-13	2007-02-20	Teva Pharmaceutical Industries Ltd.	Process for the preparation of rosuvastatin
US7439373B2 (en) *	2004-07-20	2008-10-21	TEVA Gyógyszergyár Zártkörúen Múködö Részvénytársaság	Crystalline mycophenolate sodium
CN1976894A (zh) *	2004-07-22	2007-06-06	特瓦药物精化学品股份有限公司	阿托莫西汀盐酸盐的多形体
CN101068814A (zh) *	2004-09-04	2007-11-07	特瓦制药工业有限公司	分离的伐昔洛韦杂质，制备伐昔洛韦杂质的方法及其作为参比标准物的应用
US20060081361A1 (en) *	2004-09-13	2006-04-20	Gabbey Lawrence W	Oil cooler with integral filter
US7674923B2 (en) *	2004-09-28	2010-03-09	Teva Pharmaceutical Industries Ltd	Process for preparing forms of atorvastatin calcium substantially free of impurities
WO2006045120A2 (en) *	2004-10-19	2006-04-27	Teva Pharmaceutical Industries Ltd.	Purification of tegaserod maleate
US7678551B2 (en) *	2004-10-25	2010-03-16	Seradyn, Inc.	Immunoassays for lamotrigine
TWI306858B (en) *	2004-12-23	2009-03-01	Teva Pharma	Process for preparing pharmaceutically acceptable salts of duloxetine and intermediates thereof
US20060173215A1 (en) *	2005-01-11	2006-08-03	Valeriano Merli	Process for the preparation of 1-amino-3,5-dimethyladamantane hydrochloride
US20070037979A1 (en) *	2005-02-22	2007-02-15	Valerie Niddam-Hildesheim	Preparation of rosuvastatin
US20070167625A1 (en) *	2005-02-22	2007-07-19	Anna Balanov	Preparation of rosuvastatin
CA2683975A1 (en) *	2005-02-22	2006-08-31	Teva Pharmaceutical Industries Ltd.	Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
CA2602073A1 (en) *	2005-02-24	2006-08-31	Teva Pharmaceutical Industries Ltd.	Processes for the preparation of linezolid intermediate
EP1858874A1 (en) *	2005-03-14	2007-11-28	Teva Pharmaceutical Industries Ltd.	(s)-n,n-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl) propanamine-di-p-toluoyl-l-tartarate and methods of preparation thereof
JP2008501721A (ja) *	2005-04-05	2008-01-24	テバファーマシューティカルファインケミカルズソチエタレスポンサビリタリミテ	安定性アトモキセチン塩酸塩、その調製方法及びその安定性の分析的調節
US7417165B2 (en) *	2005-04-06	2008-08-26	Teva Pharmaceutical Industries Ltd.	Crystalline forms of pregabalin
WO2006110783A2 (en) *	2005-04-11	2006-10-19	Teva Pharmaceutical Industries Ltd.	Process for making (s)-pregabalin
US7488846B2 (en) *	2005-04-11	2009-02-10	Teva Pharmaceuical Industries Ltd.	Pregabalin free of lactam and a process for preparation thereof
EP1869007A1 (en) *	2005-04-14	2007-12-26	Teva Pharmaceutical Industries Ltd	Process for preparing quetiapine fumarate
US20080280977A1 (en) *	2005-04-26	2008-11-13	Sandor Molnar	Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid
KR100893312B1 (ko) *	2005-05-10	2009-04-15	테바 파마슈티컬 인더스트리즈 리미티드	프레가발린 및 이의 염의 제조 방법
WO2006121557A1 (en) *	2005-05-10	2006-11-16	Teva Pharmaceutical Industries Ltd.	Pregabalin free of lactam and a process for preparation thereof
KR20070067077A (ko) *	2005-05-10	2007-06-27	테바 파마슈티컬 인더스트리즈 리미티드	이소부틸글루타르산을 함유하지 않는 프레가발린 및 이의제조 방법
WO2006122259A1 (en) *	2005-05-10	2006-11-16	Teva Pharmaceutical Industries Ltd.	Optical resolution of 3-carbamoylmethyl-5-methyl hexanoic acid
WO2006127932A2 (en)	2005-05-23	2006-11-30	Teva Pharmaceutical Industries Ltd.	Purification of cinacalcet
BRPI0605902A (pt) *	2005-06-27	2007-12-18	Sicor Inc	processo de purificação para intermediário de anastrozol
WO2007002720A2 (en) *	2005-06-27	2007-01-04	Sicor, Inc.	An impurity of anastrozole intermediate, and uses thereof
CN101213177A (zh) *	2005-07-05	2008-07-02	特瓦制药工业有限公司	孟鲁司特的纯化
US7868169B2 (en) *	2005-08-16	2011-01-11	Teva Pharmaceutical Industries, Ltd.	Crystalline rosuvastatin intermediate
WO2007035890A1 (en)	2005-09-19	2007-03-29	Teva Pharmaceutical Industries Ltd.	An asymmetric synthesis of ( s ) - ( + ) -3- (aminomethyl) -5-methylhexanoic acid
US20070197529A1 (en) *	2005-12-01	2007-08-23	Viviana Braude	Isolated desfluoro-linezolid, preparation thereof and its use as a reference marker and standard
US7759500B2 (en) *	2005-12-05	2010-07-20	Teva Pharmaceutical Industries Ltd.	2-(N-methyl-propanamine)-3-(2-naphthol)thiophene, an impurity of duloxetine hydrochloride
WO2007069264A2 (en) *	2005-12-15	2007-06-21	Alembic Limited	Reference standards for determining the purity of telithromycin and processes therefor
WO2007076159A2 (en) *	2005-12-27	2007-07-05	Teva Pharmaceutical Industries Ltd.	Pure darifenacin hydrobromide substantially free of oxidized darifenacin and salts thereof and processes for the preparation thereof
MX2007014913A (es) *	2006-03-27	2008-10-24	Teva Pharma	Proceso para perparar clorhidrato de memantina sustancialmente libre de impurezas.
US20080146675A1 (en) *	2006-04-05	2008-06-19	Eugenio Castelli	Stable Atomoxetine Hydrochloride, a process for the preparation thereof, and an analytical control of its stability
GB0609835D0 (en) *	2006-05-18	2006-06-28	Pliva Istrazivanje I Razvoj D	Impurities of a pharmaceutical product
WO2007139933A2 (en) *	2006-05-24	2007-12-06	Teva Pharmaceutical Industries Ltd.	Processes for the preparation of r-(+)-3-(carbamoyl methyl)-5-methylhexanoic acid and salts thereof
EP2071032A3 (en) *	2006-05-31	2009-07-08	Teva Pharmaceutical Industries Ltd	The use of enzymatic resolution for the preparation of intermediates of pregabalin
US20080015385A1 (en) *	2006-05-31	2008-01-17	Lilach Hedvati	Preparation of (S)-pregabalin-nitrile
EP2032712B1 (en) *	2006-06-29	2010-02-10	Ivax Pharmaceuticals S.R.O.	Regulation of acid metabolite production
US20120142919A1 (en) *	2006-08-02	2012-06-07	Medichem, S.A.	Method for synthesizing lamotrigine
CN101506178A (zh) *	2006-08-14	2009-08-12	隆沙有限公司	制备拉莫三嗪的方法
EP2139845A1 (en) *	2007-02-26	2010-01-06	Teva Pharmaceutical Industries Ltd.	Intermediates and processes for the synthesis of ramelteon
WO2008118427A2 (en) *	2007-03-22	2008-10-02	Teva Pharmaceutical Industries Ltd.	Synthesis of (s)-(+)-3-(aminomethyl)-5-methyl hexanoic acid
WO2008127663A1 (en) *	2007-04-11	2008-10-23	Teva Gyógyszergyár Zártköruen Muködo Részvénytársaság	Method for reducing impurity level in mycophenolic acid fermentation
WO2008151170A2 (en) *	2007-05-31	2008-12-11	Teva Pharmaceutical Industries Ltd.	Process for the synthesis of ramelteon and its intermediates
KR20090101462A (ko) *	2007-10-03	2009-09-28	테바 파마슈티컬 인더스트리즈 리미티드	프레가발린-4-엘리미네이트, 프레가발린 5-엘리미네이트, 기준 마커 및 표준물로서의 이들의 용도, 및 이들을 낮은 수준으로 함유하는 프레가발린의 제조 방법
KR20100058660A (ko) *	2007-10-23	2010-06-03	테바 파마슈티컬 인더스트리즈 리미티드	다사티닙 다형체 및 이의 제조 방법
US20090281176A1 (en) *	2007-11-01	2009-11-12	Vinod Kumar Kansal	Process for the synthesis of ramelteon and its intermediates
US8486927B2 (en) *	2007-11-09	2013-07-16	Thar Pharmaceuticals	Crystalline forms of lamotrigine
EP2252574A1 (en) *	2008-03-06	2010-11-24	Teva Pharmaceutical Industries Ltd.	Processes for the preparation of o-desmethylvenlafaxine, free from its dimer impurities
US20100087525A1 (en) *	2008-06-23	2010-04-08	Lilach Hedvati	Stereoselective enzymatic synthesis of (s) or (r)-iso-butyl-glutaric ester
US20100152468A1 (en) *	2008-10-16	2010-06-17	Teva Pharmaceutical Industries Ltd.	Process for the synthesis of ramelteon and its intermediates
KR101409554B1 (ko) *	2010-03-29	2014-06-19	플리바 흐르바츠카 디.오.오.	Ｏ-데스메틸벤라팍신 푸마레이트의 결정형
WO2012034065A1 (en)	2010-09-09	2012-03-15	Teva Pharmaceutical Industries Ltd.	Aliskiren intermediates and a process for analyzing the purity of aliskiren
CN102766104A (zh) *	2012-08-20	2012-11-07	三金集团湖南三金制药有限责任公司	一种治疗双向情感障碍及癫痫病药物拉莫三嗪的合成方法
WO2015092819A2 (en) *	2013-12-21	2015-06-25	Nektar Therapeutics (India) Pvt. Ltd.	Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5- amine
CN110467560B (zh)	2018-05-09	2025-11-25	深圳微芯生物科技股份有限公司	一种苯基氨基丙酸钠衍生物、其制备方法和应用
KR102270026B1 (ko) *	2020-01-31	2021-06-28	현대약품 주식회사	(3s)-3-(4-(3-(1,4-다이옥사스파이로[4,5]데스-7-엔-8-일)벤질옥시)페닐)헥스-4-이노익산의 품질 평가 방법
CN113156009B (zh) *	2021-04-20	2023-12-22	三金集团湖南三金制药有限责任公司	高效液相色谱分析拉莫三嗪的方法
US12605388B2 (en)	2024-09-25	2026-04-21	Azurity Pharmaceuticals Ireland Limited	Lamotrigine salts, co-crystals, and compositions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0021121B1 (en)	1979-06-01	1983-05-11	The Wellcome Foundation Limited	1,2,4-triazine derivatives, process for preparing such compounds and pharmaceutical compositions containing them
JPS5625170A (en)	1979-06-01	1981-03-10	Wellcome Found	Triazine derivative
GB8613183D0 (en)	1986-05-30	1986-07-02	Wellcome Found	Triazine salt
GB9426448D0 (en) *	1994-12-30	1995-03-01	Wellcome Found	Process
WO1996020934A1 (en) *	1994-12-30	1996-07-11	The Wellcome Foundation Limited	Process for the preparation of lamotrigine
GB9512854D0 (en) *	1995-06-23	1995-08-23	Wellcome Found	Novel formulation

1998
- 1998-06-10 GB GBGB9812413.4A patent/GB9812413D0/en not_active Ceased
1999
- 1999-02-24 EA EA199900159A patent/EA000666B1/ru not_active IP Right Cessation
- 1999-02-25 SG SG9901252A patent/SG85628A1/en unknown
- 1999-03-09 HR HR990074A patent/HRP990074A2/hr not_active Application Discontinuation
- 1999-03-09 KR KR1019990007632A patent/KR100322354B1/ko not_active Expired - Fee Related
- 1999-03-10 AT AT99200695T patent/ATE218552T1/de not_active IP Right Cessation
- 1999-03-10 AU AU20319/99A patent/AU2031999A/en not_active Abandoned
- 1999-03-10 PL PL99331870A patent/PL331870A1/xx not_active Application Discontinuation
- 1999-03-10 CN CN99103445A patent/CN1238454A/zh active Pending
- 1999-03-10 DK DK99200695T patent/DK0963980T3/da active
- 1999-03-10 NZ NZ334590A patent/NZ334590A/xx unknown
- 1999-03-10 ZA ZA9901951A patent/ZA991951B/xx unknown
- 1999-03-10 ID IDP990201D patent/ID22957A/id unknown
- 1999-03-10 PE PE1999000190A patent/PE20000332A1/es not_active Application Discontinuation
- 1999-03-10 SI SI9930088T patent/SI0963980T1/xx unknown
- 1999-03-10 ES ES99200695T patent/ES2178342T3/es not_active Expired - Lifetime
- 1999-03-10 EP EP01203376A patent/EP1170588A1/en not_active Withdrawn
- 1999-03-10 TR TR1999/00520A patent/TR199900520A3/tr unknown
- 1999-03-10 AR ARP990101018A patent/AR014074A1/es not_active Application Discontinuation
- 1999-03-10 PT PT99200695T patent/PT963980E/pt unknown
- 1999-03-10 HU HU9900592A patent/HUP9900592A3/hu unknown
- 1999-03-10 AP APAP/P/1999/001481A patent/AP9901481A0/en unknown
- 1999-03-10 US US09/265,670 patent/US6333198B1/en not_active Expired - Fee Related
- 1999-03-10 EP EP99200695A patent/EP0963980B1/en not_active Expired - Lifetime
- 1999-03-10 YU YU12399A patent/YU12399A/sh unknown
- 1999-03-10 NO NO991151A patent/NO991151L/no unknown
- 1999-03-10 DE DE69901656T patent/DE69901656T2/de not_active Expired - Fee Related
- 1999-03-10 BR BR9900984-6A patent/BR9900984A/pt not_active IP Right Cessation
- 1999-03-10 MA MA25489A patent/MA24777A1/fr unknown
- 1999-03-10 JP JP11063792A patent/JP2989189B1/ja not_active Expired - Fee Related
- 1999-03-10 CA CA002265194A patent/CA2265194C/en not_active Expired - Fee Related
- 1999-03-10 AP APAP/P/2001/002286A patent/AP0102286A0/en unknown
2000
- 2000-01-17 UY UY25946A patent/UY25946A1/es unknown
- 2000-07-25 CN CN00122208A patent/CN1306210A/zh active Pending
2001
- 2001-09-06 AP AP2001002286A patent/AP2001002286A0/xx unknown
2003
- 2003-06-17 NO NO20032753A patent/NO20032753D0/no unknown

Also Published As

Publication number	Publication date
SI0963980T1 (en)	2002-12-31
YU12399A (sh)	2002-08-12
AP9901481A0 (en)	1999-03-31
JP2000009714A (ja)	2000-01-14
ES2178342T3 (es)	2002-12-16
AR014074A1 (es)	2001-01-31
HUP9900592A3 (en)	2002-04-29
EP0963980A2 (en)	1999-12-15
NZ334590A (en)	2000-07-28
KR100322354B1 (ko)	2002-02-07
ZA991951B (en)	1999-08-16
ID22957A (id)	1999-12-23
TR199900520A2 (en)	2000-01-21
HUP9900592A2 (hu)	2000-04-28
HU9900592D0 (en)	1999-04-28
DK0963980T3 (da)	2002-09-16
SG85628A1 (en)	2002-01-15
PL331870A1 (en)	1999-12-20
AP0102286A0 (en)	2000-09-10
BR9900984A (pt)	2000-05-02
US6333198B1 (en)	2001-12-25
AU2031999A (en)	2000-01-06
AP2001002286A0 (en)	2001-12-31
CN1306210A (zh)	2001-08-01
PT963980E (pt)	2002-10-31
EP0963980B1 (en)	2002-06-05
ATE218552T1 (de)	2002-06-15
TR199900520A3 (tr)	2000-01-21
CA2265194C (en)	2000-10-10
UY25946A1 (es)	2000-12-29
EP1170588A1 (en)	2002-01-09
NO20032753L (no)	1999-12-13
NO991151D0 (no)	1999-03-10
CN1238454A (zh)	1999-12-15
DE69901656D1 (de)	2002-07-11
EP0963980A3 (en)	2000-05-31
DE69901656T2 (de)	2003-01-30
MA24777A1 (fr)	1999-10-01
JP2989189B1 (ja)	1999-12-13
HRP990074A2 (en)	2000-10-31
EA000666B1 (ru)	2000-02-28
EA199900159A1 (ru)	1999-12-29
KR20000005611A (ko)	2000-01-25
PE20000332A1 (es)	2000-04-10
NO20032753D0 (no)	2003-06-17
GB9812413D0 (en)	1998-08-05

Publication	Publication Date	Title
AP0102286A0 (en)	2000-09-10	Compound and its use.
WO2003050505A3 (en)	2004-01-29	Method of analyzing components of alveolar breath
ATE345339T1 (de)	2006-12-15	N-heterocyclische derivate als nos inhibitoren
CO5450244A1 (es)	2004-10-29	Derivados de adenina
CY1115472T1 (el)	2017-01-04	Ενωσεις αμινοετεροαρυλιου ως αναστολεις κινασων πρωτεϊνων
DE60239552D1 (de)	2011-05-05	Messung der protein-syntheseraten bei menschen und in experimentellen systemen durch verwendung von isotopisch markiertem wasser
NO913074D0 (no)	1991-08-07	Fremgangsmaate og mekanisme for supersonisk separering av draaper fra gass-stroem.
EA199800374A1 (ru)	1998-10-29	Ингибитор протеинкиназы с
NO984080D0 (no)	1998-09-04	Nye arylglycinamid-derivater, fremgangsmÕte for fremstilling derav og blandinger som inneholder disse forbindelser
CY1105137T1 (el)	2010-03-03	Παραγωγα αμινοκυκλοεξυλ αιθερων και χρησεις τους
DE60314441D1 (de)	2007-07-26	Analyse pharmazeutischer löslichkeit und stabilität
FI922587A0 (fi)	1992-06-04	Merocyaninindikatorer foer proteinfel.
IT1293778B1 (it)	1999-03-10	1,4,7,10-tetraazabiciclo(8.2.2.)tetradecan-2 one, sua preparazione e suo uso per la preparazione di tetraazamacrocicli
DE69320339D1 (de)	1998-09-17	Derivate des Dolastatin
ES2171018T3 (es)	2002-08-16	Uso de agentes inmunomoduladores.
DE69725459D1 (de)	2003-11-13	Substituierte 1,2,3,4-tetrahydro-2-dibenzofuranamine und 2-aminocyclohepta(b)benzofurane
BR9912307A (pt)	2001-05-02	Inibidores fkbp
BR9908796A (pt)	2000-10-31	Uso de compostos de macrolìdeo, método de tratamento e prevenção de ards, composição farmacêutica e composto macrolìdeo
NO20001937D0 (no)	2000-04-13	2-substituerte 1,2-benzisotiazol-derivater og deres anvendelse som serotonin-antagonister (5-HT1A, 5-HT1B og 5-HT1D)
NO890589L (no)	1989-08-14	Fremgangsmaate ved fremstilling av polyalkylperylener, perylener oppnaadd ved en slik fremgangsmaate, og organiske materialer med esr egenskaper avledet fra disse.
DE69827614D1 (de)	2004-12-23	Chinoxalindionen
CY1106705T1 (el)	2012-05-23	Δοκιμασια για μετρηση ολο-τρανσκοβαλαμινης και φολικου
MXPA04003084A (es)	2004-09-06	Portador de muestras con pinzas.
DE59911481D1 (de)	2005-02-24	Ionisationsrauchmelder
ATE244714T1 (de)	2003-07-15	1-(3-aminoindazol-5-yl)-3-phenylmethyl cyclische harnstoffe und ihre verwendung als hiv protease inhibitoren